04/06/2020 (Agence Europe) – On Wednesday June 3, the World Health Organization (WHO) announced the resumption of clinical trials on hydroxychloroquine, after the journal The Lancet distanced itself from the study concluding that this molecule derived from the antimalarial drug chloroquine (see EUROPE 12493/9) was ineffective or even risky. On the European side, the Discovery teams will also examine the possibility of reintegrating new patients. “Discovery’s steering committee [...] will consider resuming inclusions in the hydroxychloroquine treatment group”, the French public health institute (Inserm), which is overseeing the study, told the French news agency (AFP) on Thursday 4 June. (SPj)